WebMar 9, 2024 · This retrospective cohort study analyzed data from the QuintilesIMS Formulary Impact Analyzer (FIA) database across 3,472 patients requesting access to Repatha or Praluent ® (alirocumab) from ... WebFARXIGA may increase the risk of diabetic ketoacidosis (increased ketones in your blood or urine) in people with type 1 diabetes. FARXIGA is not for use to improve blood sugar …
FDA Advisory Committee
WebSYMBICORT Cost and Patient Assistance Programs SYMBICORT® (budesonide/formoterol fumarate dihydrate) Inhalation Aerosol. The information below … Web‡IQVIA Formulary Impact Analyzer (FIA) audit, 3 months ending December 2024, average based on 30-day Rx supply. § For eligible commercially insured patients only. Subject to applicable insurance plan’s eligibility rules and requirements; restrictions may apply. AstraZeneca’s Commitment to Access and Affordability got assistir online
Available IQVIA Data - IQVIA
WebAug 1, 2006 · The role of cost- and pharmacoeconomic-related criteria in formulary decision-making was assessed in a literature review of 31 studies of hospital (n=18) and managed care (n=13) pharmacy and therapeutics (P&T) committees. In both settings, cost was important, although the elements of cost considered varied. WebJun 15, 2024 · In the study, investigators looked at patterns of claims, out of pocket costs, and treatment persistence reported over four years in the IQVIA Formulary Impact Analyzer. More than 3,000 patients with and without copay assistance were included in claims data analysis, and over 1,500 patients were analyzed for treatment persistence. WebNov 13, 2024 · This retrospective cohort study used linked pharmacy adjudication status (IQVIA Formulary Impact Analyzer [FIA]; IQVIA, Plymouth Meeting, PA, USA), medical and prescription claims (IQVIA Dx/LRx or PharMetrics Plus [P+]), and laboratory data (Prognos, New York, NY, USA) from July 1, 2013, to December 31, 2024 . The FIA is a … gotas sophipren ofteno